Table 1.

Safety results of the network meta-analysis.

Comparison	Adverse event	Adverse event, serious	Adverse event, treatment-related
Hylan G-F 20 vs IACS OR (95% Crl)	1.32 (0.94, 1.93)	0.53 (0.05, 2.53)	2.72 (0.83, 9.75)

CrI, credible interval; IACS, intra-articular corticosteroid; OR, odds ratio.